Developing Patient-Centered, Evidence-Based Treatment Plans for Multiple Sclerosis
Developing Patient-Centered, Evidence-Based Treatment Plans for Multiple Sclerosis is organized by Prime Education, LLC.
Release Date: March 30, 2023
Expiration Date: March 29, 2024
Description:
To keep pace with the ever-changing therapeutic landscape in multiple sclerosis (MS), care teams must not only stay current with and incorporate the latest information about safety, efficacy, and side effects, but also factor in patient preferences and goals into treatment decision making.
This program offers a comprehensive look into developing patient-centered treatment plans for MS. Through real-world patient insights, expert strategies and latest advances, as well as individualized care techniques, attendees will gain the knowledge and the skills necessary for creating successful treatment plans for their MS patients.
Join us for this educational program featuring:
• Expert faculty insights on integrating patient perspectives and novel therapies into personalized treatment plans
• Best practices for assessment and monitoring of symptoms and treatment response
• Latest advances and clinical data in the MS therapeutic landscape
• Real-world patient perspectives in MS care management
• This activity is delivered in partnership with ACTRIMS.
Agenda:
• Evidence-Based Monitoring, Assessment of MS Symptoms and Treatment Response, and Identifying When to Switch Therapy
• Differentiating Current and Emerging Disease Modifying Therapies
• Expert Strategies in Making Timely, Evidence-Based, and Individualized Treatment Selections
Learning Objectives:
• Evaluate real world insights from patient with multiple sclerosis (MS) to bridge gaps in patient provider communication, shared decision making, and adherence to MS treatment plans
• Differentiate current and emerging disease-modifying therapies (DMTs) based on safety and efficacy, as well as considerations for administration and patient access
• Develop expert strategies that integrate clinical evidence and patient specific characteristics into decisions on initial DMT selection, evaluation of treatment response and disease progression, and DMT switching.